

## MUSC Health Pharmacy Department Publications – 2019-2024

Publication Year	Pharmacy resident involved?	Pharmacy student involved?	Citation
2024	n	n	Sperry JD, Loeb A, Smith MJ, Brighton TB, Ehret JA, Fermo JD, Gentili ME, Lancaster JW, Mazur JN, Spezzano K, Szwak JA. Retrospective multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity. <i>J Thromb Thrombolysis</i> April 2024; 57: 603-612.
2024	n	n	Bell CM, Rech MA, Boateng KA, Kastotakis G, McMurray JD, Moses BA, Mueller SW, Patel GP, Roberts RJ, Sakhuja A, Setliff K, Droege CA. Ketamine in Critically Ill Adult Patients: Use, Perceptions, and Potential Barriers. <i>Journal of Pharmacy Practice</i> . April 2024;37(2):351-363.
2024	y	n	Bui VT, Pfeifer C, Snelgrove DK, Neyens RR. Pain Assessment Following Opioid Administration in Aneurysmal Subarachnoid Hemorrhage Associated Headache. <i>J Pharm Practice</i> Apr 2024. doi 10.1177/08971900241248481. Online ahead of print. PMID 38627957
2024	n	n	Holger DJ, Alhubyani A, Morrisette T, Rebold N, Tailor M. Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: a focus on BPaL and BPaLM. <i>Pharmacotherapy</i> . 2024 Jan. doi: 10.1002/phar.2909.
2024	n	n	Condeni MS. Case Series: Perioperative management of patients in the ICU. <i>J Am Coll Clin Pharm</i> 2024;7:589-612.
2024	n	n	Condeni MS, Weant KA, Neyens RR, Eriksson EA, Miano TA. Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis. <i>Am J Emerg Med</i> 2024;77:91-105.
2024	y	n	Pizzuti M, Bailey P, Derrick C, Albrecht B, Carr AL, Covington EW, Deri CR, Green SB, Hayes J, Hobbs ALV, Mediwala Hornback K, Keil E, Lukas J, Seddon M, Taylor AD, Torrisi J, Bookstaver PB. Epidemiology and treatment of invasive <i>Bartonella</i> spp. infections in the United States. <i>Infection</i> . 2024. doi: 10.1007/s15010-024-02177-1.
2024	n	n	Davis JA, Dima D, Ahmed N, et al. Impact of frailty on outcomes after chimeric antigen receptor t cell therapy for patients with relapsed/refractory multiple myeloma. <i>Transplantation and Cellular Therapy</i> . 2024;30(3):298-305.
2024	n	n	Gagelmann N, Dima D, Merz M, et al. Development and validation of a prediction model of outcome after b-cell maturation antigen-directed chimeric antigen receptor t-cell therapy in relapsed/refractory multiple myeloma. <i>JCO</i> . 2024;42(14):1665-1675.
2024	n	n	Hashmi H, Hansen DK, Peres LC, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. <i>Haematologica</i> . 2024;109(5):1514-1524.
2024	n	n	Afrough A, Hashmi H, Hansen DK, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. <i>Blood Cancer J</i> . 2024;14(1):1-5.
2024	n	n	Zanwar S, Sidana S, Shune L, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. <i>J Hematol Oncol</i> . 2024;17(1):42.
2024	n	n	Graf KC, Davis JA, Cendagorta A, et al. “fast but not so furious”: a condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myeloma. <i>eJHaem</i> . 2024;5(4):793-797.
2024	n	n	Davis JA, McGann M, Marini J, Hashmi H. How to manage prolonged immune effector cell-associated hematotoxicity (Icaht) related to BCMA-directed myeloma therapy. <i>Expert Review of Anticancer Therapy</i> . 2024;24(6):335-338.
2024	n	n	Moore DC, Granger K, Hill H, Karabinos A, Davis JA. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> . 2024;17(6):197-200.
2024	n	n	Goel U, Dima D, Davis J, et al. Safety and efficacy of B cell maturation antigen -directed CAR T -cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis. <i>European J of Haematology</i> . Published online August 27, 2024:ejh.14293.
2024	n	n	Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. <i>JADPRO</i> . 2024;15(8).

MUSC Health Pharmacy Department Publications – 2019-2024

2024	n	n	McGann M and Gautama B. Management of cytopenia post-chimeric antigen receptor T-cell therapy. <i>Pharmacy Practice in Focus: Oncology</i> . 2024 August;6(6):14-17.
2024	n	n	Wesson W, Dima D, Suleman N, Davis J, McGann M, et al. Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma. <i>Transplantation and Cellular Therapy</i> . 2024 June;1-9. doi: 10.1016/j.jtct.2024.06.012
2024	y	n	Dietz L, Marini J, Hashmi H, McGann M. A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. <i>J Oncol Pharm Practice</i> . 2024. doi: 10.1177/10781552241247472.
2024	y	y	Trac C, Zecopoulos A, Ross C, Weeda E, McGraw D. Comparison of weight-based valproic acid dosing in treatment of mental illness among obese and nonobese patients. <i>J Clin Psychopharmacol</i> . 2024;44:468-71.
2024	n	n	Zacholski E, MacDonald JE, Hayward S. Ocular Toxicity of Antibody-Drug Conjugates Used in Gynecologic Malignancies. <i>Journal of Hematology Oncology Pharmacy</i> . Accepted. In print 12/2024.
2024	y	n	Nickelsen PM, Neyens R, Al Kasab S. Clopidogrel hyperresponsiveness and hemorrhagic complications using on-label clopidogrel dosing after pipeline embolization. <i>J Pharm Practice</i> 2024. Ahead of Print. doi: 10.1177/08971900241273311
2024	n	n	Amer M, Moller MH, Alshahrani M, Shehabi Y, Arabi YM, Slishamsi F, Sigurosson MI, Rehn M, Chew M, Kalliomaki M, Lewis K, SI-Suwaidan FA, Al-Dorzi HM, Al-Fares A, Alsadoon N, Bell CM, Groth C, Park R, Mehta S, Wischmeyer P, Omeri A, Olkkola K, Alhazzani W. Ketamine Analgo-sedation for Mechanically Ventilated Critically Ill Adults: A Rapid Practice Guideline from the Saudi Critical Care Society and the Scandinavian Society of Anesthesiology and Intensive Care Medicine. <i>Acta Anaesthesiologica Scandinavica</i> . 2024;1–18.
2024	n	n	Amer M, Moller MH, Alshahrani M, Shehabi Y, Arabi YM, Slishamsi F, Sigurosson MI, Rehn M, Chew M, Kalliomaki M, Lewis K, SI-Suwaidan FA, Al-Dorzi HM, Al-Fares A, Alsadoon N, Bell CM, Groth C, Park R, Mehta S, Wischmeyer P, Omeri A, Olkkola K, Alhazzani W. Ketamine Analgo-sedation for Mechanically Ventilated Critically Ill Adults: A Rapid Practice Guideline from the Saudi Critical Care Society and the Scandinavian Society of Anesthesiology and Intensive Care Medicine. <i>Anesthesia &amp; Analgesia</i> (>):10.1213/ANE.0000000000007173, August 29, 2024
2024	y	n	Davis DM, Jackson K, Hoppe C. Evaluation of cost and infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars at an academic medical center. <i>J Oncol Pharm Pract</i> . 2024 Feb 12:10781552241231913. doi: 10.1177/10781552241231913. Epub ahead of print. PMID: 38347722.
2024	n	n	Cummings K, Toll B, Ware E, et al. Implementation, enrollment, and engagement in an opt-out telehealth pharmacist-assisted tobacco treatment program for patients seen in oncology outpatient clinics. <i>Cancer</i> . 2024; 1-11. doi:10.1002/cncr.35291
2024	n	n	Fahey MC, Carpenter MJ, Ware E, et al. Expectations and Preferences for Digital Cessation Treatment: Multimethods Study Among Older Adults Who Smoke Cigarettes. <i>J Med Internet Res</i> 2024;26:e52919. doi: 10.2196/52919. PMID: 39196628. PMCID: 11391153
2024	n	n	Nielsen EM, Ware EC, Heincelman M, Schreiner AD, Lenert LA, Toll BA. Prescription of Nicotine Replacement Therapy for Hospitalized Tobacco Users. <i>South Med J</i> . 2024 Aug;117(8):517-520. doi: 10.14423/SMJ.0000000000001719. PMID: 39094806.
2024	n	y	Maldonado Yanez BV, Kerrara KE, Lueking R, Morrisette T, Brewer EE, Lewis NH, Burgoon R, Mediwala Hornback K, Hamby AC. Comparison of the impact of a system tele-antimicrobial stewardship program on the conversion of intravenous-to-oral antimicrobials in community hospitals. <i>Antimicrob Steward Healthc Epidemiol</i> . 2024 Oct;4(1):e159
2024	y	n	Persha H, Thacker SA, Mediwala Hornback K, Alvira-Arill GR, Lueking R, Morrisette T. Real-world clinical characteristics and outcomes with daptomycin use in pediatric patients: a retrospective case series. <i>Antibiotics (Basel)</i> . 2024 Sep;13(9):883.
2024	n	y	Morrisette T, Alghamdi S, Maree MB, Dixon TC, Thacker SA. One and done? An evaluation of the clinical outcomes of single- and multi-dose dalbavancin use in the pediatric population. <i>J Pharm Pract</i> . 2024 Sep;8971900241285521. doi: 10.1177/08971900241285521.
2023	y	n	Ngo S, Weeda E, Malloy K. Comparison of outcomes in neonates receiving cefepime or ceftazidime. <i>J Pediatr Pharmacol Ther</i> . 2023;28(5):439-445.

## MUSC Health Pharmacy Department Publications – 2019-2024

2023	y	n	Hartley C, Morrisette T, Malloy K, Steed LL, Dixon T, Garner SS. Successful eradication of a highly resistant <i>Elizabethkingia anophelis</i> species in a premature neonate with bacteremia and meningitis. <i>Pediatr Infect Dis J</i> . 2023 Dec;42(12):e461-e465.
2023	y	n	Koscal LJ, Meadows H, Raux BR, Mediwalla KN, Weeda E, Houston B, Jandhyala D, Hawn JM. Evaluation of the impact of nasal colonization with methicillin-resistant <i>Staphylococcus aureus</i> on left ventricular assist device infections. <i>ASHE</i> . 2022;2(1):e79
2023	n	n	Heavner MS, Cucci MD, Barlow B, Aldhaeefi M, Thompson Bastin ML, Bell CM, Eng CC, Erdman G, Hawkins WA, Li M, Rose C, Smith SE, Lankford A. Caring for two in the ICU: pharmacologic management of pregnancy-related complications. <i>Pharmacotherapy</i> . June 2023; 00: 1-16.
2023	n	n	Heavner MS, Erdman G, Barlow B, Aldhaeefi M, Cucci M, Eng CC, Hawkins WA, Rose C, Smith SE, Bell CM, Lankford A, Li M, Thompson Bastin ML. Caring for two in the ICU: Pharmacotherapy in the critically ill pregnant patient. <i>Pharmacotherapy</i> . March 2023;43(5):403-418.
2023	n	n	Lajthia O, Almallouhi E, Ali H, Essibayi MA, Bass E, Neyens R, Anadani M, Chalhouh R, Kicielinski K, Lena J, Porto G, Sattur M, Spiotta A, Al Kasab S. Failed Mechanical Thrombectomy: prevalence, etiology, and predictors. <i>J of Neurosurgery</i> 2023; doi:10.3171/2022.12.JNS222152. [epub ahead of print]
2023	n	n	Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, KangOBirken SL, Hobbs ALV, Agree J, Perkins 3rd NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. <i>Microbiol Spectr</i> . 2023 Nov: e0235123.
2023	n	n	Holger DJ, El Ghali A, Bhutani N, Lev KL, Stamper K, Kebriaei R, Kunz Coyne AJ, Morrisette T, Shah R, Alexander J, Lehman SM, Rojas LJ, Marshall SH, Bonomo RA, Rybak MJ. Phage-antibiotic combinations against multidrug-resistant <i>Pseudomonas aeruginosa</i> in in vitro static and dynamic biofilm models. <i>Antimicrob Agents Chemother</i> . 2023 Oct: e0057823.
2023	n	n	El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, Wadle C, Phillely JV, Mejia-Chew C, Hamad Y, Steevens RW, Zeuli JD, Webb AJ, Fiske CT, Simonyan A, Cimino CL, Mammadova M, Umana VE, Hasbun R, Butt S, Molina JC, Thomas M, Kaip EA, Bouchard J, Gore TW, Howard C, Cabanilla MG, Holger DJ, Frens JJ, Barger M, Ong A, Cohen KA, Rybak MJ. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. <i>Antimicrob Agents Chemother</i> . 2023 Sep; e0082423.
2023	n	n	Morrisette T, Stamper KC, Lev KL, Kebriaei R, Holger DJ, Abdul-Mutakabbir JC, Kunz Coyne AJ, Rybak MJ. Evaluation of omadacycline alone and in combination with rifampin against <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> in an in vitro pharmacokinetic/pharmacodynamic biofilm model. <i>Antimicrob Agents Chemother</i> . 2023 Jun;67(6):e0131722.
2023	n	n	Tran NN, Morrisette T, Jorgensen SCJ, Orench-Benvenutti JM, Kebriaei R. Current therapies and challenges for the treatment of <i>Staphylococcus aureus</i> biofilm-related infections. <i>Pharmacotherapy</i> . 2023 May. doi: 10.1002/phar.2806.
2023	n	n	Feldman A, Sell M, et al. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. <i>JAMA Network Open</i> . 2023;6(10):e2337602
2023	n	n	Chudow MB, Condeni MS, Dhar S, Heavner MS, Nei AM, Bissell BD. Current Practice Review in the Management of Acute Respiratory Distress Syndrome. <i>J Pharm Pract</i> 2023;36(6):1454-71.
2023	n	n	Ryan KL, Jeffres M, Mediwalla Hornback K, Lusardi K, Hirsch EB. Adding Antimicrobial Stewardship Pharmacists to the ID Compensation Discussion: A More Perfect Union? <i>Clin Infect Dis</i> . 2023:ciad722. doi: 10.1093/cid/ciad722.
2023	n	n	Adema J, Ahiskali A, Fida M, Mediwalla Hornback K, Stevens R, Rivera C. The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. <i>Pathogens</i> . 2024; 13(3): 190; <a href="https://doi.org/10.3390/pathogens13030190">https://doi.org/10.3390/pathogens13030190</a>
2023	n	n	Lapin J, Smith R, Mediwalla Hornback K, Claeys KC. Relationship between Bloodstream Infection Rapid Diagnostics and Antimicrobial Stewardship: A Narrative Review and Practical Considerations for Implementation. <i>Pharmacotherapy</i> . 2023 May 9. doi: 10.1002/phar.2813.

MUSC Health Pharmacy Department Publications – 2019-2024

2023	n	n	Mediwala Hornback, K. 2023 ASHP Pharmacotherapy Specialty Review and Recertification Course "Infectious Diseases - Part II". BCPS Review Course Modules. American Society of Health-Systems Pharmacists. 2023.
2023	y	n	Davis JA, Granger K, Roubal K, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. <i>Blood</i> . 2023;141(2):200-203.
2023	n	n	Ferreri CJ, Hildebrandt MAT, Hashmi H, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. <i>Blood Cancer J</i> . 2023;13(1):1-9.
2023	n	n	Davis JA, Sborov DW, Wesson W, et al. Efficacy and safety of cd34+ stem cell boost for delayed hematopoietic recovery after bcma directed car t-cell therapy. <i>Transplant Cell Ther</i> . 2023;29(9):567-571.
2023	n	n	Dima D, Davis JA, Ahmed N, et al. Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience. <i>Transplantation and Cellular Therapy</i> . 2024;30(3):308.e1-308.e13.
2023	y	n	Thurlapati A, Roubal K, Davis JA, et al. Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real- world experience. <i>Transplantation and Cellular Therapy</i> . 2023;29(5):340.e1-340.e4.
2023	n	n	Sidana S, Peres LC, Hashmi H, et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. <i>Haematologica</i> . 2023;109(3):777-786.
2023	y	n	Granger K, Gaffney KJ, Davis JA. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. <i>J Oncol Pharm Pract</i> . 2023;29(3):722-726.
2023	n	n	Dima D, Rashid A, Davis JA, et al. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa -1 trial eligibility criteria: A real-world multicentre study. <i>Br J Haematol</i> . 2024;204(4):1293-1299.
2023	n	n	Wesson W, Ahmed N, Rashid A, et al. Safety and efficacy of eltrombopag in patients with post- CAR T cytopenias. <i>European J of Haematology</i> . 2024;112(4):538-546.
2023	n	n	Peres LC, Oswald LB, Dillard CM, et al. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. <i>Blood Adv</i> . 2024;8(1):251-259.
2023	y	n	Davis JA, Granger K, Sakowski A, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> . 2023;16(12):915-918.
2023	y	n	Thurlapati A, McGann M, Davis JA, et al. Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients. <i>Journal of Medical Virology</i> . 2023;95(8):e29027.
2023	y	n	McGann M, Velayati A, Roubal K, et al. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies. <i>Leukemia &amp; Lymphoma</i> . 2023;64(9):1592-1595.
2023	y	y	Davis JA, Thurlapati A, Weeda E, et al. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. <i>Ann Hematol</i> . 2024;103(1):251-258.
2023	n	n	Davis JA, Misniakiewicz J, Hendrickson L, McGann M, Herbst A, Hess BT. Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy. <i>Ann Hematol</i> . 2023;102(2):461-462.
2023	n	n	Davis JA, Graham A, Hendrickson L, Hess B, Gaffney K. Incidence of Pneumocystis jirovecii pneumonia (Pjp) in patients receiving BTK inhibitors who did not receive PJP prophylaxis. <i>Leukemia &amp; Lymphoma</i> . 2022;63(8):2016-2018.
2023	n	n	Khouri J, Dima D, Li H, et al. Absolute lymphocyte count and outcomes of multiple myeloma patients treated with idecabtagene vicleucel: the us myeloma immunotherapy consortium real- world experience. <i>Transplantation and Cellular Therapy</i> . 2024;30(8):790.e1-790.e16.
2023	n	n	Dima D, Abdallah AO, Davis JA, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor t-cell therapy. <i>Blood Cancer J</i> . 2024;14(1):1-9.

MUSC Health Pharmacy Department Publications – 2019-2024

2023	y	y	Thurlapati A, Wesson W, Davis JA, et al. Impact of cytogenetic abnormalities, induction and maintenance regimens on outcomes after high-dose chemotherapy and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a decade-long real-world experience. <i>J Hematol.</i> 2023;12(6):243-254.
2023	y	n	Granger K, Gaffney KJ, Smith D, et al. Real world outcomes of cpx-351 compared to traditional chemotherapy with cytarabine consolidation for treatment of secondary acute myeloid leukemia. <i>Blood.</i> 2023;142(Supplement 1):5922-5922.
2023	y	y	Gaffney KJ, Bakos JK, Velayati A, et al. Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. <i>J Oncol Pharm Pract.</i> Published online January 2, 2024:10781552231224360.
2023	n	n	McGann M, Gaffney KJ, Davis JA, Smith D, Hashmi H. Organ toxicities associated with chimeric antigen receptor T-cell therapy. <i>Leukemia &amp; Lymphoma.</i> 2023;64(2):491-494.
2023	y	n	Granger K, Roubal K, Davis JA. Novel Bispecific Antibodies for the Treatment of Multiple Myeloma and Non-Hodgkin Lymphoma. <i>HOPA News.</i> 2023
2023	n	n	Hall TR, MacDonald JE, Bylinowski KM, Alvarez EA, Hardesty MM, Smith JA. Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement. <i>Gynecol Oncol.</i> 2023 Oct;177:180-185. doi: 10.1016/j.ygyno.2023.08.017. Epub 2023 Sep 15. PMID: 37717346.
2023	n	n	Rimel BJ, Crane EK, Hou J, Nakayama J, MacDonald J, Lutz K, Makker V, O’Cearbhaill R. Tyrosine kinase inhibitor toxicities: a society of gynecologic oncology review and recommendations. <i>Gynecol Oncol.</i> 2023;174:148-156.
2023	y	n	Marini J, Maldonado A, Weeda E, Hashmi H, Neppalli A, Edwards K. Efficacy, safety and cost implications of outpatient autologous hematopoietic stem cell transplant for multiple myeloma. <i>Hematology/Oncology and Stem Cell Therapy.</i> 2023;16(4). and <i>Stem Cell Therapy.</i> 2023;16(4).
2022	y	n	Burgoon R, Hamby A, Weeda E, Raux BR, Hornback KM. Risk factors for predicting extended-spectrum $\beta$ -lactamase-producing Enterobacterales (ESBLE) infections in non-urinary isolates. <i>Antimicrob Steward Healthc Epidemiol.</i> 2023;3(1):e123. Published 2023 Jul 11. doi:10.1017/ash.2023.201
2022	n	n	Bixby ML, Raux BR, Bhalla A, McCoy C, Hirsch EB. Opportunities for antibiotic stewardship in emergency department of hospitalized patients with asymptomatic bacteriuria: identifying risk factors for antibiotic treatment. <i>Antimicrob Steward Healthc Epidemiol.</i> 2022 Jan;2(1):e16
2022	n	n	Vest TA, Bell CM, Adelman A, Musch KLE, Latiolais CA, Martin CY, Whalen KM. Supplying the pipeline of peer review: a call to engage new practitioners. <i>American Journal of Health-System Pharmacy.</i> May 2022; 79:718-20
2022	n	n	Bell CM, Vest TA, White S. Dealing with Doubt: Overcoming Imposter Syndrome in New Practitioners. <i>American Journal of Health-System Pharmacy.</i> March 2022; 79:421-3.
2022	n	n	Morrisette T, Alosaimy S, Lagnf AM, Frens JJ, Webb AJ, Veve MP, Stevens R, Bouchard J, Gore TW, Ansari I, Rybak MJ. Real-world, multi-center case series of patients treated with omadacycline for resistant Gram-negative pathogens. <i>Infect Dis Ther.</i> 2022 Aug;11(4):1715-1723.
2022	n	n	Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success. <i>Open Forum Infect Dis.</i> 2022 May;9(6):ofac028.
2022	n	n	FahkriRavari A, Simiyu B, Morrisette T, Dayo Y, Abdul-Mutakabbir JC. Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy. <i>Drugs Context.</i> 2022 Jan;11:2021-8-9.
2022	n	n	Sikora AS, Ayyala D, Rech M, Blackwell SB, Campbell J, Caylor MM, Condeni MS, DePriest A, Dzierba AL, Flannery AH, Hamilton LA, Heavner MS, Horng M, Lam J, Liang E, Montero J, Murphy D, Plewa-Rusiecki AM, Sacco A, Sacha GL, Shah P, Smith MP, Smith Z, Radosevich JJ, Viella AL, The MRCICU Investigator Team. Impact of pharmacists to improve patient care in the critically ill: A large multicenter analysis using meaningful metrics. <i>Crit Care Med</i> 2022;50(9):1318-28.



MUSC Health Pharmacy Department Publications – 2019-2024

2022	n	y	McManus J, Ferreira J, Jones GM, Smetana K, Condeni MS, Berger K, Witenko C, Pizzi M, Erdman M. Association of DDAVP on outcomes in spontaneous acute intracerebral hemorrhage in patients on antiplatelet therapy. <i>J Neurol Sci</i> 2022; 434:120142.
2022	n	n	Mazur JM, Condeni MS. "Intra-abdominal Infections" in Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB, ed. <i>Pharmacotherapy Principles and Practice</i> , 6th ed. New York, NY: McGraw-Hill Education 2022.
2022	n	n	Cawcutt KA, Marcelin JR, Cortes-Penfield N, Cutrell JB, Dong S, Mahoney MV, McCarty T, Mediwala Hornback K, Titanji BK, Woc-Colburn L, Schwartz IS. #SoMe the Money! Value, Strategy, & Implementation of Social Media Engagement for Infectious Diseases Trainees, Clinicians, and Divisions. <i>Clin Infect Dis</i> . 2022;74(Supplement_3):S229-S236. doi: 10.1093/cid/ciac063.
2022	y	n	Beechinor RJ, Eche IM, Edmonds N...Mediwala KN, et al. Perceptions of a virtual interview process for pharmacy residents during the COVID-19 pandemic: A multisite survey of residency candidates, preceptors, and residency program directors. <i>Am J Health-Syst Pharm</i> . 2022;zxac130. doi: 10.1093/ajhp/zxac130.
2022	n	n	Mediwala Hornback, K. 2022 Pharmacotherapy Core Therapeutic Modules "Infectious Diseases - Part II". BCPS Review Course Modules. American Society of Health-Systems Pharmacists. 2022.
2022	y	n	Davis J, McGann M, Shockley A, Hashmi H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma. <i>Expert Review of Hematology</i> . 2022;15(6):473-475.
2022	n	n	McGann M, Davis JA, Gaffney KJ, et al. Real-world experience and optimization of outpatient chimeric antigen receptor t cell therapy. <i>Transplantation and Cellular Therapy</i> . 2022;28(9):583-585.
2022	y	n	Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (Bcma) targeting immunotherapy in multiple myeloma. <i>J Oncol Pharm Pract</i> . 2022;28(4):960-968.
2022	y	n	Davis JA, Shockley A, Glode AE. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma. <i>J Oncol Pharm Pract</i> . 2022;28(3):686-690.
2022	n	n	Davis JA, Rizzieri DA, Lane AA, et al. Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (Bpdcn). <i>Leukemia &amp; Lymphoma</i> . 2022;63(11):2757-2759.
2022	y	n	Davis JA, Shockley A, Herbst A, Hendrickson L. Polatuzumab vedotin for the front-line treatment of diffuse large b-cell lymphoma: a new standard of care? <i>J Adv Pract Oncol</i> . 2023;14(1):67-72.
2022	y	n	Hashmi H, Shockley A, Davis JA. 'Save the day with a Stem Cell Rescue': Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. <i>Bone Marrow Transplant</i> . 2022;57(3):504-506.
2022	y	n	Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy. <i>Clinical Lymphoma Myeloma and Leukemia</i> . 2022;22(8):e680-e684.
2022	y	n	Shockley A, Davis JA, Gaffney KJ, Smith D, Weeda E, Hashmi H. Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant. <i>J Oncol Pharm Pract</i> . 2022;28(7):1613-1616.
2022	y	n	Shockley A, Davis JA. B-Cell Maturation Antigen Targeting CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. <i>HOPA News</i> . March/April, 2022
2022	n	n	Gaffney KJ, Davis JA, McGann M, et al. Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy. <i>J Oncol Pharm Pract</i> . 2024;30(1):151-158.
2022	n	n	Gaffney KJ, McGann M, Davis JA, Edwards KH, Hashmi H. The incidence and characteristics of VTE within 100 days of CAR T-cell therapy. <i>Ann Hematol</i> . 2023;102(3):683-685.
2022	n	n	Davis JA, Gaffney KJ, McGann M, et al. Fever characteristics and impact on safety and efficacy of chimeric antigen receptor t-cell therapy. <i>Clinical Lymphoma Myeloma and Leukemia</i> . 2023;23(1):e14-e18.

MUSC Health Pharmacy Department Publications – 2019-2024

2022	n	n	Hashmi H, McGann M, Greenwell BI. Use of long-term corticosteroids in patients treated with CAR T-cell therapy. <i>J Oncol Pharm Practice</i> . 2022 Mar;29(2):473-476. doi: 10.1177/10781552221104816.
2022	y	y	Marini J, Bass B, Rennebaum J, Weeda E, Misniakiewicz J, Sion A. The Link Between Hypoalbuminemia and Oral Tyrosine Kinase Inhibitor Adverse Events in Adults with Malignant Solid tumors. <i>J Hematol Oncol Pharm</i> . Aug 2022;12(4):196-203.
2022	y	n	Slane A, Robert S, Rarrick C, Weeda E. Survey of noncontrolled medication misuse patterns. <i>Ment Health Clin</i> 2022;12(3):199-204.
2022	n	n	Foster M, Toll B, Ware E, et al. Optimizing the Implementation of Tobacco Treatment for People with HIV: A Pilot Study. <i>Int J Environ Res Public Health</i> . 2022 Oct 8;19(19):12896. doi: 10.3390/ijerph191912896. PMID: 36232195; PMCID: PMC9566573.
2021	y	n	Burgoon R, Weeda E, Mediwala KN, Raux BR. Clinical utility of negative methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) nasal surveillance swabs in skin and skin structure infections. <i>Am J Infect Control</i> . 2022;50(8):941-946. doi:10.1016/j.ajic.2021.12.005
2021	y	n	Wiethorn EE, Harrison S, Weeda ER, Bell CM. Effectiveness and Safety of Twice- versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. <i>Annals of Pharmacotherapy</i> . May 2022; 56:541-7.
2021	y	n	Barre S, Mcelwee J, Calhoun C, Weant KA, Maldonado A, Bell CM. Review of Hematologic and Oncologic Emergencies. <i>Advanced Emergency Nursing Journal</i> . April-June 2022; 44:84-
2021	y	y	Fabick A, Hawn J, Weeda E, Goodwin AJ, Bell CM. Comparison of Extravasation Events Related to the Administration of Vasoactive Medications via a Peripheral Intravenous Line Prior to and Following Implementation of an Institutional Protocol. <i>Journal of the American College of Clinical Pharmacy</i> . June 2023; 6(7): 709- 717.
2021	y	n	Morgan EP, Hawn JM, Meadows H, Houston B, Tedford RJ, Fajardo J, Perez C. Evaluation of aspirin platelet inhibition in left ventricular assist device. <i>J Card Surg</i> . 2021;36(12):4503-4508.
2021	n	n	Rebold et al. Early multicenter experience with imipenem-cilastatin-relebactam for Multidrug-resistance gram-negative infections. <i>Open Forum Infect Dis</i> . 2021 Dec;8(12):ofab554
2021	n	n	Spiegel MC, Simpson A, Davis A, Philip A, Bell CM, Nadig NR, Ford DW, Goodwin AJ. Finding the Balance: A Quality Improvement Initiative to Improve Evidence-Based Isotonic Fluid Prescribing. <i>International Journal of Medical Informatics</i> . December 2021; 156: 104619.
2021	n	n	Ammar M, Ammar A, Condeni MS, Bell CM. Narrative Review on the Role of Vitamin C in Sepsis and Septic Shock. <i>American Journal of Therapeutics</i> . July 2021;28:e649-79.
2021	n	n	Bell CM, Procter L, Parli S. Asystole following concomitant intravenous administration of neostigmine and dexmedetomidine in a patient with acute colonic pseudo-obstruction. <i>Journal of Pharmacy Practice</i> . March 2021. doi:10.1177/08971900211001278. Online Ahead of Print.
2021	n	n	Condeni MS, Basting AT, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Bell CM, McLean B, Reichert M, Santibanez M, Wieruszewski PM, Newsome AS. Major publications in the critical care pharmacotherapy literature: 2019. <i>Journal of Critical Care</i> . April 2021. 197-205.
2021	n	n	Hecht K, Bolton S, Elavsky M, Bell CM, McElray K, Hancock B, Adams A. Navigating the Roadmap of Workplace Politics: Advice for New Practitioners. <i>American Journal of Health-System Pharmacy</i> . January 2021; 78:89-92.
2021	n	n	Pilch N, Sell ML, McGhee W, Venkataramanan R. Important considerations in drug therapy in pediatric transplants. <i>Pediatric Transplantation</i> . 2021;25:e13881
2021	n	n	Bissell B, Campbell J, Collins R, Cook C, Desai D, DeWitt J, Eche IM, Eche IJ, Elsamadisi P, Juul J, Kim SM, Makowski C, Mylvaganam R, Smith A, Stancati J, Stonsifer K, Tawil J, Condeni MS. Major publications in the critical care pharmacotherapy literature: 2020. <i>Crit Care Explor</i> 2021; 3(12): e0590.
2021	n	n	Ammar M, Ammar A, Condeni MS, Bell CM. Vitamin C in sepsis and septic shock. <i>Am J Ther</i> 2021; 28(6): e649-79.

MUSC Health Pharmacy Department Publications – 2019-2024

2021	n	n	Condeni MS, Basting AT, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Bell CM, McLean B, Reichert M, Santibanez M, Wieruszewski PM, Newsome AS. Major publications in the critical care pharmacotherapy literature: 2019, J Crit Care 2021; 62:197-205.
2021	y	y	Deloney L, Condeni MS, Carter C, Leon S, Privette A, Eriksson EA. Methocarbamol Reduces Opioid Use and Length of Stay in Young Adults with Traumatic Rib Fractures. Ann Pharmacother 2021;55(6):705-10.
2021	n	n	Lichvar AB, Condeni MS, Pierce DR. Preparing Pharmacy Trainees for a Future in Research and Contributing to the Medical Literature. J Am Coll Clin Pharm 2021;4(1):71-80.
2021	n	n	Green SB, Stover KR, Barber K, Bouchard JL, Brown ML, Deri CR, Francis BJ, Gauthier TP, Hayes JE, Marx AH, McGee EU, Mediwala K, Musgrove RJ, Slain D, Stramel SA, Bland CM, Bookstaver PB. A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2020. Open Forum Infect Dis. 2021;8(9):ofab422. doi: 10.1093/ofid/ofab422.
2021	y	n	Takamura K, Hebbard AM, Robert S. Characterization of inpatient care for patients admitted to a psychiatric hospital with a home opioid prescription. Ment Health Clin. 2021 Mar 31;11(2):55-58. doi: 10.9740/mhc.2021.03.055. PMID: 33850683; PMCID: PMC8019545.
2021	y	n	Mathew AM, Robert S, Ross C, Weeda E, Pruitt A. Impact of holding home stimulant(s) on agitation in a child and adolescent inpatient psychiatric population. Ment Health Clin 2021;11(2):50-54
2020	y	n	Wiethorn E, Bell CM, Wiggins BS. Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing $\geq$ 120 kilograms versus 60 to 120 kilograms. American Journal of Cardiovascular Drugs. March 2021; 21:545-551.
2020	y	n	Hauser C, Bell CM, Zamora RA, Mazur J, Neyens R. Characterization of Opioid Use in the Intensive Care Unit and its Impact Across Care Transitions. Characterization of Opioid Use in the Intensive Care Unit and Its Impact Across Care Transitions: A Prospective Study. Journal of Pharmacy Practice. April 2024;37(2):343-350.
2020	n	n	Bissell BD, Wieruszewski PM, Newsome AS, Verkerk BS, Witenko CJ, Ammar MA, Magee CA, Pajoumand M, Smith MN, Hammond DA. Fluid management and deresuscitation practices – An opportunity for collaboration. Journal of the Intensive Care Society. June 2020. doi:10.1177/1751143720934386
2020	n	n	Rhoney DH, La M, Merz M, Cook A, Owusu KA, Roels C, Blunck J, Shewmaker J, Sangha KS, Farrokh S, Lewin J, Chester KW, Human T, Bledsoe K, Greene K, Levesque M, Rocker JC, Davis G, Neyens R, Lassiter TF, Adriance SM. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage. Neurocrit Care 2020; doi: 10.1007/s12028-020-01153-5. [epub ahead of print]
2020	n	n	Panos NG, Cook AM, Sayona J, Jones GM, Neurocritical Care Society (NCS) Pharmacy Study Group. Factor Xa-Inhibitor-Related Intracranial Hemorrhage: Results from a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation 2020;141:1681-1689.
2020	n	n	Wang D, Champion-Lyons E, Neyens R, Bohm N, Caddell B, Babic N. The Effect of Sample Handling on Free Valproic Acid Levels. J Appl Lab Med 2020; doi:10.1093/jalm/jfaa181 [epub ahead of print].
2020	n	n	Wiggins BS, Dixon DL, Neyens R, Page RL, Gluckman TJ. Select Drug-Drug Interactions with Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol 2020;75:1341-1350.
2020	n	n	Wang D, Emanuel AJ, Neyens R, Bakharev E, Babic N. Cefoxitin-Serum Creatinine Interference in a Patient With Nontuberculosis Mycobacteria Ventriculomeningitis. J Pharm Pract 2020; doi:10.1177/0897190020921613 [epub ahead of print].
2020	y	n	Neyens R, Donaldson C, Andrews C, Kellogg R, Spiotta A. Platelet Function Testing with a VerifyNow-Directed Personalized Antiplatelet Strategy and Associated Rates of Thromboembolic Complications after Pipeline Emoblization for Complex Cerebral Aneurysms. World Neurosurg 2020;138:e674-682.



## MUSC Health Pharmacy Department Publications – 2019-2024

2020	n	n	Bissell B, Wieruszewski P, Newsome AS, Verkerk B, Witenko C, Ammar M, Magee CA, Pajoumand M, Condeni MS, Hammond DA. Fluid management and deresuscitation practices – an opportunity for collaboration. J Intensive Care Society 2020: DOI:10.1177/1751143720934386.
2020	n	n	Hammond DA, Smith MN, Peksa GP, Trivedi A, Balk R, Menich BE. Midodrine as an adjuvant to intravenous vasopressor agents in adults with resolving septic shock: systematic review and individual patient data meta-analysis. J Intens Care Med. 2020;35(11):1209-15.
2020	n	y	Griffith N, Justo JA, Winders H, Al-Hasan M, Mediwala KN, Bookstaver, PB. Implementation, Regulatory Approval, and Outcomes of a Pharmacist- and Pharmacy Trainee-Administered Penicillin Allergy Assessment and Skin Testing Program. J Am Coll Clin Pharm. 2020;3:1269-1279. doi: 0.1002/jac5.1317.
2020	y	n	Pillinger KE, Bouchard J, Withers S, Mediwala KN, Mcgee EU, Gibson GM, Bland CM, Bookstaver PB. Inpatient antibiotic stewardship interventions in the adult oncology and hematopoietic stem cell transplant population: a review of recent literature. Ann Pharmacother. 2020;54(6):594-610. doi: 10.1177/1060028019890886.
2020	n	n	Mahoney MV, Mediwala KN. Clostridioides difficile and other intra-abdominal infections. Pharmacotherapy Self-Assessment. American College of Clinical Pharmacy. 2020
2020	y	n	Thomas D, Cooper JC, and Maas M. Neuron Model of Interprofessional Education and Evidence-based Practice. Innovations in Pharmacy 2020;11(3).
2020	y	y	Rarrick C, Saccone N, Hebbard A, Jones B. Assessing the Rate of Antipsychotic Use in Ambulatory Care Patients With a Venous Thromboembolism. Ann Pharmacother. 2020 Feb;54(2):97-104. doi: 10.1177/1060028019870874. Epub 2019 Aug 16. PMID: 31416330.
2020	y	y	Rarrick C, Leschorn H, Hebbard A. Impact of a urinary tract infection diagnostic and treatment algorithm for psychiatric inpatients with a communication barrier. Ment Health Clin. 2020 Mar 30;10(2):55-59. doi: 10.9740/mhc.2020.03.055. PMID: 32257733; PMCID: PMC7108801.
2020	y	n	Rarrick C, Hebbard A. Creation and implementation of a urinary tract infection diagnostic and treatment algorithm for psychiatric inpatients with a communication barrier. Ment Health Clin. 2020 Mar 30;10(2):64-69. doi: 10.9740/mhc.2020.03.064. PMID: 32257735; PMCID: PMC7108799.
2020	n	n	Robert S. Traumatic brain injury and mood disorders. Ment Health Clin 2020;10(6):335-345.
2020	y	y	Halavonich L, Robert S, McGraw D, Weeda E, Mullinax K, Bass B. Management of delirium at an academic medical center: plans for antipsychotic prescribing upon discharge. Men Health Clin 2020 Jan;10(1):25-29
2019	y	n	MacVane SH, Raux BR, Smith TT. Evaluation of rapid polymerase chain reaction-based organism identification of gram-positive cocci for patients with a single positive blood culture. Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1471-1479
2019	n	n	Magee CA, Neyens RR, Fleming JN. Critique of implications of opioid epidemic for critical care practice. Journal of the American College Clinical Pharmacy. June 2019;2:446.
2019	n	n	Magee CA, Thompson Bastin ML, Graves K, Burgess D, Nestor M, Lamm JR, Cook AM. Fever Burden in Patients With Subarachnoid Hemorrhage and the Increased Use of Antibiotics. Journal of Stroke Cerebrovascular Diseases. November 2019; 28:1043139.
2019	n	n	Bissell B, Magee CA, Moran P, Thompson Bastin ML, Flannery AF. Hemodynamic Instability Following Vasopressin Withdrawal in Septic Shock. Journal of Intensive Care Medicine. September 2019; 34: 761-765.
2019	n	n	Lewin JJ 3rd, Cook AM, Gonzales C, Merola D, Neyens R, Peppard WJ, et al. Current Practices of Intraventricular Antibiotic Therapy in the Treatment of Meningitis and Ventriculitis: Results from a Multicenter Retrospective Cohort Study. Neurocritical Care 2019;30:609-616.
2019	n	n	Hammond DA, Lam SW, Rech MA, Smith MN, Westrick J, Trivedi AP, Balk RA. Balanced crystalloid versus saline solutions in critically ill adults: a systematic review and meta-analysis. Ann Pharmacother 2019; 54: 5-13.
2019	n	n	Newsome AS, Bissell BD, Burry LD, Defayete AA, Gagnon DJ, Gilbert BW, Kramer CJ, Miller CJ, Semanco M, Smith MN, Hammond DA. Major publications in critical care pharmacotherapy literature in 2018. J Crit Care. 2019; 52: 200-207.

MUSC Health Pharmacy Department Publications – 2019-2024

2019	y	y	Smith MN, Deloney L, Carter C, Weant K, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. <i>J Thromb Thrombolysis</i> 2019; 48: 250-5.
2019	n	n	Hammond DA, McCreary EK, Rech MA, Smith MN, Yeo QM, Lusardi K, Rhodes NJ, Swanson J, Bland CM. Perceptions and practices for beta-lactam antibiotic dosing, administration, and monitoring in critically ill patients: current views and use among critical care and infectious diseases pharmacists. <i>J Am Coll Clin Pharm</i> 2019;2:468-76.
2019	n	n	Smith MN, Brotherton AL, Lusardi K, Tan CA, Hammond DA. Systematic review of the clinical utility of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) nasal screening for MRSA pneumonia. <i>Ann Pharmacother</i> 2019; 53: 627-38.
2019	n	n	Mazur JM, Smith MN. "Intra-abdominal Infections" in Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB, ed. <i>Pharmacotherapy Principles and Practice</i> , 5th ed. New York, NY: McGraw-Hill Education 2019.
2019	y	n	Khalil AJ, Mediwalla KN, Mehta MJ, et al. Survey of residency program directors' attitudes and perceptions of non-traditional pharmacy residency applicants. <i>Am J Health Syst Pharm</i> . 2019;76(21):1788-1793. doi: 10.1093/ajhp/zxz191.
2019	n	n	Chahine EB, Durham SH, Mediwalla KN, et al. A baker's dozen of top antimicrobial stewardship intervention publications in 2018. <i>Open Forum Infect Dis</i> . 2019;6(11):ofz450. doi: 10.1093/ofid/ofz450.
2019	y	n	Fenn NE III, Nolt VD, Mediwalla KN, Sandgren MJ, Martin CY. Perceptions of the two-phase pharmacy residency match process. <i>Am J Health-Syst Pharm</i> . 2019;76(24):2041-2047. doi: 10.1093/ajhp/zxz249.
2019	n	y	Mediwalla KN, Kohn JE, Bookstaver PB, et al. Syndrome-specific versus prospective audit and feedback interventions for reducing use of broad-spectrum antimicrobial agents. <i>Am J Infect Control</i> . 2019;47(11):1284-1289. doi: 10.1016/j.ajic.2019.04.175.
2019	y	n	Seddon MM, Bookstaver PB, Justo JA, Kohn JE, Rac H, Haggard E, Mediwalla KN, Dash S, and Al-Hasan MN. Role of early de-escalation of antimicrobial therapy on risk of <i>Clostridioides difficile</i> infection following Enterobacteriaceae bloodstream infections. <i>Clin Infect Dis</i> . 2019;69(3):414-420. doi: 10.1093/cid/ciy863.
2019	n	n	Hastings E, Poon J, Robert S, Nyp S. Attention-deficit hyperactivity disorder, disruptive behaviors, and drug shortage. <i>J Dev Behav Pediatr</i> 2019;40:489-491
2019	y	n	Cooler J, Ross CA, Robert S, Linder L, Ruhe AM, Philip A. Evaluation and Optimization of Take-Home Naloxone in an Academic Medical Center. <i>Ment Health Clin</i> 2019 Mar;9(2):105-109.
2019	y	n	Nichols TA, Robert S, Taber DJ, Cluver J. Alcohol Withdrawal-Related Outcomes Associated With Gabapentin Use in an Inpatient Psychiatric Facility. <i>Ment Health Clin</i> 2019 Jan;9(1):1-5.